BioSpace News Archive

Bruker Introduces Enhanced 3D Holographic Stimulation for Optogenetics on its Ultima 2Pplus Multiphoton Microscope.

Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an exclusive licensing agreement for the registration and commercialization of NVK002 in Canada, Mexico, and select South American Countries.

Actinogen Medical Limited recently announced positive results for Part A of its two-part double-blind placebo-controlled XanaMIA dose-ranging trial, which confirmed Xanamem’s ability to rapidly enhance attention and working memory.

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced they have entered an agreement to acquire Pega Medical, including its Fassier-Duval Telescopic Intramedullary System™ designed for patients suffering from Osteogenesis Imperfecta and other bone deformities.

The South African Health Products Regulatory Authority has approved a sweet-tasting, heat-stable, ‘4-in-1' fixed-dose combination of four antiretroviral treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF.

CivicaScriptTM, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and EmsanaRx, PBC, the only pharmacy benefit manager built by employers, for employers, announced that EmsanaRx is joining CivicaScript as a partnering member.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.

AnaBios is pleased to announce the hire of Blake Anson, Ph.D., as Vice President of Business Development.

Hollister Incorporated, a global medical device company has been awarded an AscenDrive contract with Premier, Inc. AscenDrive is Premier’s new program designed to drive commitment and savings for members through aggregated purchasing of high quality products and services.